Spanish data analytics company Sequentia Biotech has secured €10 million in funding to power its software designed to advance the fields of genomics, transcriptomics, epigenomics and microbiomics, with funding from the European Union (EU).
The money was primarily managed by French venture capital firm Seventure Partners, with additional investment from the European Innovation Council (EIC) Fund, a European Commission initiative aimed at accelerating start-ups across the continent.
The funds will allow Sequentia to more quickly bring its software, designed to examine patients’ microbiomes, to market and translate its findings into actionable steps for doctors or as part of personalized medicine systems. The company says that in addition to healthcare, the MICK software can also have applications in the fields of biomedicine and agritechnology.
Walter Sanseverino, CEO of Sequentia Biotech, said: “We are pleased to announce this fundraising and our support from Seventure Partners and the EIC Fund, two highly reputable venture capital investors with strong track records of backing innovative companies in the life sciences- sector. This investment will play an important role in advancing our mission to unlock the full potential of omics and accelerate the adoption of MICK by researchers and healthcare professionals worldwide.”
The EIC fund comes as the agency looks to fill gaps in its funding and invest in supporting companies in the development and commercialization of what it calls disruptive technologies, with the participation of private investment groups.
Riccardo Aiese Cigliano, Scientific Director of Sequentia Biotech, said: “We believe we are on the cusp of a new era in omics research and in our view this investment is a signal of the market’s confidence in our vision and MICK’s potential to disrupt the market. the status quo. Our MICK platform offers a major leap forward for multiple health applications, from precision nutrition and wellness, to understanding biological processes and diseases, to creating microbiome-based treatments and therapies.
Elsewhere in the EU, the EIC has similarly invested in Endoron Medical’s flagship product, the catheter-based EndoStapling solution Aortoseal. Similarly, cardiology startup Acorai has raised $4.5 million in an oversubscribed round to further develop its non-invasive intracardiac pressure monitoring device, with further funding from the EIC.
“Sequentia Secures €10 Million for Multiomics Software Development” was originally created and published by Medical Device Network, a brand owned by GlobalData.
The information on this site has been included in good faith for general information purposes only. It is not intended to amount to advice on which reliance should be placed and we make no representation, warranty or guarantee, express or implied, as to its accuracy or completeness. You must obtain professional or specialist advice before taking or refraining from any action on the basis of the content on our site.